Diagnosing bone disease in patients with kidney issues

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to characterize bone morphology in patients with reduced renal function and varying levels of parathyroid hormone (PTH). It investigates the use of 18-Fluoride Positron Emission Tomography (18F-PET) as a non-invasive method to assess bone turnover and its correlation with bone histomorphologic changes. Patients with suspected high or low turnover bone disease will undergo a bone biopsy and an 18F-PET scan to determine the effectiveness of this imaging technique in differentiating between the two conditions.

Why it matters

Who can join: the full rules

Patients with reduced renal function:

Inclusion Criteria:

-≥ 18 years

* estimated Glomerular Filtration Rate (eGFR) ≤ 20 ml/min/1,73m2
* PTH \< 150 pg/ml or PTH \> 300 pg/ml

Exclusion Criteria:

* ongoing malignancy
* Allergy towards tetracyclin
* Pregnancy

Control Group:

Inclusion Criteria:

-≥ 18 years

* eGFR \>= 60 ml/min
* under examination for c prostata
* Prostatic Specific Antigen (PSA) total \<40 µg/l

Exclusion:

* Former kidney disease
* ionized calcium or PTH outside normal range
* Known metabolic bone disease
* treatment with anticoagulants
* Disturbed thrombosis and hemostasis

Where it's running

• Herlev Hospital
  Herlev, Denmark Recruiting

Study contacts

• Study coordinator: Ditte Hansen, PhD
• Email: ditte.hansen.04@regionh.dk
• Phone: +4538683868

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using microRNA to improve treatment for renal osteodystrophy

  This study is testing if a new method using microRNA can help doctors better understand bone health in people with chronic kidney disease and improve their treatment for renal osteodystrophy.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT05880914

• Rituximab for treating immune-related side effects from checkpoint inhibitors

  This small early-phase trial tests whether a single 100 mg dose of rituximab can help manage immune-related adverse events in adults with malignant melanoma who are on checkpoint inhibitors, alongside a tapering corticosteroid plan.

  Recruiting Phase 1 Herlev Hospital · Herlev, Herlev · NCT07694414

• Zinc supplement in acutely hospitalized older adults

  In people aged 65 and older who are acutely admitted to the hospital, taking 22 mg of zinc daily for 12 months is tested to see if it lowers inflammatory markers and improves health outcomes.

  Recruiting Herlev Hospital · Herlev, Region Hovedstad · NCT07672132

• Group-based follow-up for women after obstetric anal sphincter injury

  A group-based follow-up program is being tested to see if it can improve quality of life for women who had a tear at the anal sphincter after childbirth.

  Recruiting Herlev Hospital · Herlev, Capital Region · NCT07667660

• Neoadjuvant immunotherapy for high-risk eye melanoma

  This trial tests whether giving nivolumab and ipilimumab before surgery is safe and feasible for adults with high-risk uveal melanoma.

  Recruiting Phase 1 Herlev Hospital · Herlev, Herlev · NCT07501117

• Zinc supplementation in older medical patients to see if days alive and out of hospital improve

  Giving 22 mg of zinc once daily for 12 months to older medical patients in the ED is being tested to see if it helps more days alive and out of the hospital compared with not giving zinc.

  Recruiting Herlev Hospital · Herlev, Copenhagen and 1 other locations · NCT07367412

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.